company background image
EQL logo

EQL Pharma Informe acción NGM:EQL

Último precio

kr51.80

Capitalización de mercado

kr1.4b

7D

-3.4%

1Y

68.7%

Actualizada

12 Jun, 2024

Datos

Finanzas de la empresa +

EQL Pharma AB (publ)

Informe acción NGM:EQL

Capitalización de mercado: kr1.4b

Resumen de acción EQL

EQL Pharma AB (publ) se dedica al desarrollo, comercialización y venta de medicamentos genéricos a farmacias y hospitales de Suecia, Dinamarca, Noruega, Finlandia y el resto de Europa.

Acerca de la empresa

EQL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance1/6
Financial Health3/6
Dividends0/6

Recompensas

Cotiza un 48.1% por debajo de nuestra estimación de su valor justo
Se prevé un crecimiento anual de los beneficios de 47.39%

Análisis de riesgos

La deuda no está bien cubierta por el flujo de caja operativo
Alto nivel de ganancias no monetarias

Competidores de EQL Pharma AB (publ)

Humana

OM:HUM

kr1.6b

C-Rad

OM:CRAD B

kr1.4b

SyntheticMR

NGM:SYNT

kr1.2b

Dedicare

OM:DEDI

kr563.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for EQL Pharma
Historical stock prices
Current Share Pricekr51.80
52 Week Highkr55.00
52 Week Lowkr24.70
Beta0.72
1 Month Change30.48%
3 Month Change30.48%
1 Year Change68.73%
3 Year Change41.53%
5 Year Change337.13%
Change since IPO793.10%

Noticias y actualizaciones recientes

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Rentabilidad de los accionistas

EQLSE HealthcareMercado SE
7D-3.4%-3.0%-0.2%
1Y68.7%26.3%12.3%

Rentabilidad vs. Industria: EQL superó al sector Swedish Healthcare , que obtuvo un rendimiento del 5.3% el año pasado.

Rentabilidad vs. Mercado: EQL superó al mercado Swedish, que obtuvo un rendimiento del 10.3% el año pasado.

Volatilidad de los precios

Is EQL's price volatile compared to industry and market?
EQL volatility
EQL Average Weekly Movement5.5%
Healthcare Industry Average Movement5.1%
Market Average Movement5.9%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market3.5%

Precio estable de las acciones: El precio de las acciones de EQL ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EQL (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
200621Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publ) se dedica al desarrollo, comercialización y venta de medicamentos genéricos a farmacias y hospitales de Suecia, Dinamarca, Noruega, Finlandia y el resto de Europa. Ofrece productos inyectables para la atención hospitalaria y formulaciones para la atención ambulatoria. EQL Pharma AB (publ) se constituyó en 2006 y tiene su sede en Lund, Suecia.

Resumen de fundamentos de EQL Pharma AB (publ)

¿Cómo se comparan los beneficios e ingresos de EQL Pharma con su capitalización de mercado?
Estadísticas fundamentales de EQL
Capitalización bursátilkr1.43b
Beneficios(TTM)kr22.71m
Ingresos (TTM)kr264.17m

66.3x

Ratio precio-beneficio (PE)

5.7x

Ratio precio-ventas (PS)

¿Está EQL sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EQL
Ingresoskr264.17m
Coste de los ingresoskr149.12m
Beneficio brutokr115.05m
Otros gastoskr92.34m
Beneficioskr22.71m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Jun 28, 2024

Beneficios por acción (BPA)0.78
Margen bruto43.55%
Margen de beneficio neto8.59%
Ratio deuda/patrimonio67.6%

¿Cómo se ha desempeñado EQL a largo plazo?

Ver rendimiento histórico y comparativa